In two recent preliminary ruling proceedings, the ECJ has clarified key aspects of Regulation (EU) 2017/745 (MDR).
An amendment to the MedCanG has been in the pipeline for some time, but is still a long way off. Partly – or perhaps precisely – because it remains unclear when and in what form the amendments to the MedCanG will ultimately come into force, the debate surrounding remote prescriptions, mail-order pharmacies and digital care models is…
In 2025 and 2026, the Federal Court of Justice and several Higher Regional Courts ruled on the limits of permissible gratuities and promotional gifts in the pharmaceutical sector. Three issues were central to these ruling.
Trade mark law in the life sciences and healthcare sector is currently undergoing a phase of transformation.
On 11 December 2025, the European Parliament and the Council of the European Union agreed on a comprehensive reform of European pharmaceutical legislation: the EU Pharmaceutical Package.
Virtual wards and remote healthcare are reshaping the delivery of medical services. With the global telehealth market expected to reach $175.5 billion by 2026, both the UK and the EU are working to adapt their regulatory frameworks to keep pace with technological innovation and evolving patient needs.
With its proposal to simplify the Medical Device Regulation and the In-Vitro Diagnostics Regulation, the EU Commission took an important step towards reducing bureaucracy in medical device law on 16 December 2025.
Since 2017, medical cannabis can be legally prescribed under strict conditions, especially for the treatment of patients who are seriously ill or considered to be out of treatment.